Endometrial stromal sarcoma (ESC) is a rare form of malignancy arising from the stromal cells of the endometrium, the layer lining the uterus. This disease is one of the most aggressive manifestations of soft tissue tumors and can manifest as both a localized and metastatic process. ESC is often associated with a poor prognosis due to the carriage of gene mutations, low clinical expression in the early stages, and difficulties in diagnosis. There are different types of ESC, including differentiated and undifferentiated forms, which also determines the diversity of clinical manifestations and therapeutic approaches.
History of the disease and interesting historical facts
Endometrial stromal sarcoma was first described in 1974, when scientists drew attention to tumor changes in the stromal layer of the uterus. Previously, such tumors were classified as "dermatomyosarcomas" or "uterine stromal tumors." Later, with the development of medical technologies and diagnostic methods, it was recognized that ESC has its own unique morphological and genetic features. Interestingly, the first successful operations to remove such tumors were carried out only in the 1980s, which highlights the low level of understanding of this disease in previous years.
Epidemiology
Endometrial stromal sarcoma is a relatively rare disease, accounting for approximately 1-2% of all malignant uterine tumors. According to research, the incidence of ESC varies from 0.2 to 1 case per 100,000 women per year. The peak incidence occurs at the age of 40-60 years, but cases have also been reported among younger women. In addition, these tumors are most often diagnosed in women with menstrual irregularities and chronic diseases of the reproductive system.
Genetic predisposition to this disease
Genetic predisposition to endometrial stromal sarcoma is associated with several key genes, including TP53 and PTEN. Mutations in these genes can lead to impaired apoptosis and tumor cell escape from the immune system. According to a number of studies, women with Lynch syndromes, as well as other hereditary predispositions to tumors, are at increased risk of developing ESC. It is important to note that identifying genetic mutations in patients can provide additional information for developing individualized treatment plans.
Risk factors for the development of this disease
Several risk factors have been identified that contribute to the development of endometrial stromal sarcoma:
- Age: Women over 40 have an increased risk.
- The presence of chronic diseases such as diabetes and hypertension.
- Long-term use of estrogen-containing drugs without additional contraception.
- Environmental factors, including exposure to chemicals such as asbestos.
- Hereditary syndromes such as Lynch syndrome.
It is important to note that the presence of one or more risk factors does not necessarily lead to the development of the disease, but requires careful monitoring.
Diagnosis of this disease
Diagnosis of endometrial stromal sarcoma can be difficult due to the lack of specific symptoms in the early stages. The main symptoms that indicate the possible presence of ECS include:
- Abnormal vaginal bleeding.
- Pain in the pelvic area.
- Increase in abdominal size.
- Problems with urination.
Laboratory investigations may include histological analysis of the biopsy specimen and assessment of tumor marker levels. Radiological examinations such as ultrasound and MRI help to determine the stage of the disease and the size of the tumor. Differential diagnosis with other uterine tumors such as fibroids and adenomyosis is necessary, which requires the participation of experienced histopathologists.
Treatment
Treatment of endometrial stromal sarcoma is complex and includes several approaches:
- General treatment aimed at removing the tumor.
- Surgery is usually the first step and includes a hysterectomy.
- Pharmacological treatment may include the use of hormonal drugs to suppress tumor growth.
- Chemotherapy is used in cases of relapse or metastasis.
- Targeted therapy and immunotherapy are considered in the context of clinical trials.
Each case is individual, and the choice of treatment depends on the stage of the disease, the patient's age and general health.
List of medications used to treat this disease
The main medications that can be used for endometrial stromal sarcoma include:
- Doserelkin (hormonal drug)
- Paclitaxel (chemotherapeutic agent)
- Temozolomide (for cells resistant to traditional chemotherapy)
- Sorefenib (targeted therapy)
The efficacy and tolerability of each drug should be assessed individually.
Disease monitoring
Monitoring of patients with endometrial stromal sarcoma includes regular examinations to detect recurrences. Control stages are important, which include clinical examinations, laboratory tests and radiological studies. The prognosis depends on the stage of the disease at the time of diagnosis: early diagnosis significantly improves the outcome. However, there is a risk of complications such as peritonitis and recurrence, which requires constant monitoring of the patient's condition.
Age-related features of the disease
Endometrial stromal sarcoma may present differently depending on age group:
- Women under 40 often have less aggressive forms of the disease.
- Menopausal women have a higher risk of aggressive progression and metastasis.
- In postmenopause, symptoms may be masked as climacteric changes, making diagnosis difficult.
Understanding age-related characteristics allows doctors to more accurately select diagnostic and treatment methods.
Questions and Answers
- What is endometrial stromal sarcoma? It is a rare malignancy arising from endometrial stromal cells that can be aggressive and have a high risk of recurrence.
- What symptoms indicate the possibility of the disease? The main symptoms include abnormal vaginal bleeding, pelvic pain, and an increasing abdominal size.
- How is the disease diagnosed? Diagnosis includes clinical examinations, laboratory tests, radiological studies and histological examination of affected tissues.
- What treatment is used to prevent recurrence? Preventive treatment may include surgical removal of the tumor, as well as pharmacological therapy with hormonal and chemotherapeutic drugs.
- What is the prognosis for endometrial stromal sarcoma? The prognosis depends on the stage of the disease; early stages have a more favorable prognosis, while advanced cases may have a poor course and a high risk of relapse.
Dr. Oleg Korzhikov recommends paying special attention to any changes in the menstrual cycle and symptoms, such as unusual discharge or pelvic pain. "If you experience unusual symptoms, do not delay a visit to the doctor, as early diagnosis significantly improves the prognosis," he notes. In addition, the doctor warns of possible risks with long-term use of hormonal drugs without control, and strongly recommends regular preventive examinations, especially for women over 40.
